Proliferative Vitreoretinopathy (PVR) Adoption Continues to Grow: Study

Increasing medical advancements and government initiatives to bolster the sales for proliferative vitreoretinopathy treatment market

Fact.MR, Rockville MD: Award winning market research company Fact.MR has conducted a research study on global proliferative vitreoretinopathy market. As per its analysis, researchers and medical professionals are initiating and investing in R&D activities to prevent an early development of PVR in patients, boosting the demand for proliferative vitreoretinopathy.

According to National Center of Biotechnology Information, on the survey of 8 years, 42 out of 79 patients showed vision-threatening abnormalities out of which 9 patients were at the risk of retinal detachment and diagnosed with PVR. Acknowledging this the healthcare professionals are incorporating technical advancements to increase the awareness, thus maintaining a stable growth.

According to the latest study by Columbia University, although 6% of the general population are anticipated to have retinal breaks, approximately 12.5 cases per 100,000 per year registers with retinal detachment. Accounting for a very modest growth for proliferative vitreoretinopathy.

“According to the study, the intravitereal injectable are preferred over other mode of administration drugs as they are directly deliverable to retina and vitreous. Medical professionals are still researching for a beneficial treatment for PVR which is fostering the demand,” says the Fact.MR analyst.

Request a report sample to gain comprehensive insights at

Key Takeaways

  • Global proliferative vitreoretinopathy to exhibit a modest growth of nearly 4% CAGR through 2021
  • North America to vanguard the market with 2/5th of market share
  • Hospital pharmacies to remain primary end-users for proliferative vitreoretinopathy
  • Injectable to remain dominant in mode of administration of proliferative vitreoretinopathy
  • Proliferative vitreoretinopathy sales to reach nearly $660 Mn by end of forecast period

Prominent Drivers

  • Increasing awareness among policymakers and hospital pharmacies to propel the sales for proliferative vitreoretinopathy
  • Favorable government policies and reimbursements to bolster the demand for the market
  • High technological advancements and penetration of deep learning for better efficiency is surging the sales

Key Restraints

  • Risk factors like uveitis and vitreous hemorrhage to hamper the demand
  • High failure rate accounting to approximately of 75% to be the biggest obstacle for the growth of the market

Discover more about the proliferative vitreoretinopathy treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on

Competitive Landscape

Key manufacturers operating in the global proliferative vitreoretinopathy treatment market include Novartis AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Pfizer Inc., Allergan Plc., and other public & private players. The primary strategy that all the manufacturers are focusing is the increased investment in the development of new products.

In October 2019, Novartis received FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept. The same year, Novartis received positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and disease.

Also, earlier this year, in February 2021, Genentech’s Faricimab became the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients.

More Insights on the Proliferative Vitreoretinopathy Market Report

In its latest report, Fact.MR offers unbiased analysis of the global proliferative vitreoretinopathy treatment market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of distribution channel, mode of administration, drug class and across major regions (North America, Europe and Rest of the World)

Get Customization on this Report for Specific Research Solution

Explore Fact.MR’s Coverage on the Healthcare Domain

Retinal biosimilars Market: Fact.MR’s exclusive coverage on the global Retinal biosimilars market sheds light on the prominent expansion dynamics likely to play a pivotal role in furthering future growth. A detailed segment-wise and regional assessment has been embedded within the scope of this study, along with an exhaustive profiling of prominent microscopy device manufacturers present in the landscape.

Eye sockets implants Market: An extensive study by Fact.MR on the global Eye sockets implants market, analyses crucial trends which determine future expansion prospects of the landscape. Details regarding prominent manufacturers and segments across prominent regions have also been provided in this study.

Artificial Eyes Market: A detailed assessment of Artificial Eye market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in Fact.MR’s coverage on the landscape. A comprehensive estimate on asthma spacers market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of asthma spacers market during the forecast period.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.


Sudip Saha

US Sales Office:

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583

Source: Fact.MR

Back to news